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Question: What is the best available research evidence (volume, quality, consistency, gener-
alisability) for the active cycle of breathing technique (ACBT)?
Design: Systematic review with meta-analysis.
Participants: Participants with respiratory conditions characterised by chronic sputum produc-
tion.
Intervention: The active cycle of breathing or forced expiratory technique.
Comparator: All comparators including control conditions.
Outcome measures: All outcomes providing continuous data.
Results: Twenty-four studies were included. Ten comparators were identified with the most
common being conventional chest physiotherapy, positive expiratory pressure and a control.
The outcomes most frequently assessed were sputum wet weight (n Z 17), forced vital
capacity (nZ 12) and forced expiratory volume in 1 s (nZ 12). Meta-analysis was completed
on the primary outcome of sputum wet weight. The standardised mean difference (SMD,
random effects) showed an increase in sputum wet weight during and up to 1 h post ACBT
compared to conventional physiotherapy (SMD 0.32, 95%CI 0.05e0.59), external oscillatory
devices (0.75, 0.48e1.02), and control (0.24, 0.02e0.46).
Conclusion: The overall body of evidence was classified as good (good volume, quality and
consistency, excellent generalisability). High level, variable risk of bias research evidence
favours ACBT over most alternatives for short-term improvements in secretion clearance.
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The active cycle of breathing technique (ACBT) and the
forced expiratory technique (FET) are commonly used to
promote airway clearance for individuals with chronic lung
disease characterised by copious secretions. Abnormal
secretion production can potentially lead to airway
obstruction and sputum retention, thereby predisposing the
airways to infection and inflammation. Treatment methods
that aim to clear secretions may decrease the frequency of
infections, therefore preventing further airway damage and
deterioration of lung function, and potentially reducing the
rate of progression of lung disease.1,2 The FETconsists of one
or two forced expirations or huffs, followed by breathing
control (relaxed breathing).3 The FET is an integral part of
the ACBT, in conjunction with thoracic expansion exercises
and interspersed periods of breathing control.4 A typical
ACBT cycle therefore consists of breathing control, 3e4
thoracic expansion exercises, breathing control, and the
forced expiratory technique (huffing). The number and
frequency of each of the components of the ACBT can be
altered, but all components of the cycle must be present,
and interspersed with breathing control.
A number of mechanisms have been proposed as the
means by which ACBT achieves enhanced secretion clear-
ance (Fig. 1). The forced expiratory manoeuvres (low- and
high-volume huffing) are thought to promote secretion
movement through changes in thoracic pressures and
airway dynamics.5 Breathing control is reported to prevent
bronchospasm and oxygen desaturation while the thoracic
expansion exercises assist in the loosening and clearance of
secretions, and the improvement of collateral ventila-
tion.3,4 It is possible that the physiological effects of ACBT
may differ slightly across different patient populations,
depending on the degree of sputum production, stage of
disease, and whether the patient is medically stable, or in
an exacerbated state. Airway clearance techniques such as
the ACBT have been shown to result in favourable outcomes
in people with a wide range of lung disease, including non-
CF bronchiectasis,6 cystic fibrosis,7 and COPD.8
The difficulty in determining which outcomes should be
considered in reviewing the literature associated with
a technique such as the ACBT stems from the ambiguity
between short and long term goals. While it is possible that
short term goals such as improved sputum clearance mayFigure 1 Proposed mechanisms by which Flead to improved longer term health outcomes such as
improved quality of life or reduced disease progression, it
remains to be seen whether this causal chain is represented
in the current body of evidence underpinning the technique.
This review sought to identify the body of evidence
underpinning the FET and ACBT, and therefore recorded all
reported outcomes. Due to the short duration of themajority
of included studies, meta-analysis was completed only on
outcomes which were considered to reflect a short term,
airway clearance mediated effect such as sputum weight,
rather than outcomes reflecting multiple therapies (phar-
macological agents, nutrition). Actual sputum production is
a commonly used outcome measure for airway clearance
techniques in clinical practice. Clinicians have been shown
to commonly use sputum production in patient assessment,
and patients commonly consider sputum production in their
own assessment of the efficacy of airway clearance tech-
niques such as the ACBT.9,10 The outcome of sputum volume
has been identified as a relevant, inexpensive, minimally
invasive, easily accessible and clinically useful marker to
monitor response to therapy in people with cystic fibrosis11
and bronchiectasis.12 In people with bronchiectasis, daily
sputum volume has been identified as an important prog-
nostic indicator, with people with higher daily sputum
volume having poorer quality of life.13 To date, few studies
report improvements in pulmonary function as a result of
airway clearance techniques in people with chronic lung
disease during non-exacerbated states. Short and longer
term changes in pulmonary function tests (PFTs) in people
with chronic lung conditions generally cannot be solely
attributed to the impact of airway clearance techniques. It is
likely that any changes in PFTs induced by clearance tech-
niques will be small, transient and subsumed within day to
day variance of PFTs which may be as high as 15 per cent in
the forced expiratory volume in 1 s (FEV1) in people with
cystic fibrosis (CF).14 Therefore, outcomes relating to overall
lung function such as forced vital capacity (FVC) and FEV1
which reflect severity of pulmonary impairment and disease
progression were not included in the meta-analysis.
This systematic review summarised all primary data
from experimental studies of FET/ACBT in order to assess
the body of evidence for the intervention. A modified
National Health and Medical Research Council15 body of
evidence matrix used in a previous review16 was used to
assess the volume, quality, effectiveness, and consistencyET/ACBT results in secretion clearance.
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What is the best available research evidence (volume,
quality, consistency, generalisability and effectiveness) for
the therapeutic interventions of FET/ACBT?
Method
Identification and selection of studies
The databases AMED, MEDLINE, CINAHL, Scopus, Web of
Science and the Cochrane Library were searched from
inception to August 2008 (Appendix). Titles and abstracts
were screened to identify relevant studies. Citations were
retrieved as full text for more detailed evaluation of
applicability. Reference lists of all full text articles
included in the short list and all systematic reviews located
were screened. Researchers involved in the area were
invited to review the publication short list to identify any
additional studies.
Initially, citations were identified which indicated
explicitly that at least one treatment group had received
FET or ACBT in the title or abstract. Two reviewers inde-
pendently screened the initial search results for potentially
eligible studies. The reviewers resolved disagreements by
consensus. All identified studies were then retrieved in full,
as were any studies where the abstract was unavailable or
where ambiguity existed. To be included, studies were
required to use an experimental design, report primary
original data pertaining to the therapeutic techniques of
FET/ACBT, and be published in English. There were no
publication year limits.
Assessment of characteristics of studies
Quality and volume of the evidence
Risk of methodological bias was assessed using the LOW
appraisal tool.16 The presence or absence of nine criteria
was assessed by two independent reviewers with
a maximum possible score of nine. Criteria were assessed
using only the documentation provided in the publication.
Disagreements were resolved by a third independent
reviewer. Due to the focus of this review on establishing the
best research evidence for the FET/ACBT and the likelihood
that varying levels of evidence would be retrieved, the
Lloyd-Smith hierarchy of evidence,17 rather than the
NHMRC hierarchy was used as this hierarchy accounts for
the lower levels of evidence.
Generalisability of the evidence
Studies including people with respiratory conditions where
chronic sputum production was likely to be a feature (CF,
bronchiectasis, chronic bronchitis) were considered to
represent the population where FET/ACBT is indicated.
While chronic sputum production is a feature of these
conditions, it is likely that there is considerable variation in
sputum production both between and within populations,18
with the range of reported daily sputum volume differing
between people with chronic bronchitis (5 to >50ml),19 and
bronchiectasis (20e500ml).20 To date, no information could
be found which reported the average daily sputum volume
in people with cystic fibrosis. The generalisability of theincluded studies (how representative the studies were to
the population of interest) was assessed separately to the
critical appraisal (LOW tool), using a modified NHMRC body
of evidence matrix. Generalisability of the evidence was
determined by calculating the percentage of studies that
included participants with chronic sputum producing
respiratory diseases. The generalisability was classified as
excellent if greater than 90 per cent of the studies included
participants with respiratory conditions with chronic
sputum production, good (75e90%), fair (50e74%) and poor
(<50%).16
Participants
There were no restrictions placed upon the age range of
participants (children or adults) or symptoms (asymptom-
atic and participants with acute or chronic conditions).
Animal studies or papers reporting mathematical models
were excluded.
Intervention
Within the existing literature and in the clinical environ-
ment, variations occur in the definition and application of
physiotherapy treatment modalities. The ACBT was
included if it was described as containing three essential
components: 1) breathing control, 2) FET and 3) thoracic
expansion exercises. The technique may also include
postural drainage (PD) or percussion/shaking.21 Similarly,
the technique of FET was required to contain relaxation or
breathing control, and huffing, and may include PD and
percussion/shaking.
Comparators
Possible comparisons were a control or another interven-
tion. Studies which compared the intervention plus or
minus an adjunct therapy such as pharmacological agents
were excluded. For the purposes of this review, compara-
tors have been grouped together according to the following
descriptions.
Conventional physiotherapy (CPT): any combination of
PD, percussion, shaking, vibrations, huffing and directed
coughing.21
Devices which provided resistive inspiratory manoeu-
vres (RIM): adjunctive equipment which provided resis-
tance of approximately 80 per cent of the maximal
sustained inspiratory pressure.
Devices which altered airways pressure or air flow:
including oscillatory devices such as flutter and acapella,
positive expiratory pressure (PEP) devices and oral high
frequency oscillation (OHFO).
Devices which applied intermittent pressure to the
chest wall: including mechanical percussion devices such as
the Equi-med percussor and high frequency chest
compression devices such as the Hayek Oscillator.
Exercise: prescribed for the purpose of airway
clearance.
Autogenic drainage (AD): high expiratory flow rates at
varying lung volumes to increase sputum clearance and
avoid closure of the airways.
Outcome measures
All outcomes were recorded. Decisions concerning meta-
analysis were made upon completion of data extraction and
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clearance were considered for meta-analysis.
Data analysis
The relevant details about the method (study design,
participants, intervention, outcome measures) and results
(sample size, means, standard deviations, standard errors,
confidence intervals, p values, correlation coefficients)
were extracted by two independent reviewers. Data were
extracted for the outcome of sputum wet weight which
used continuous scales of measurement (interval, ratio)
either reported by authors or subsequently calculated from
published data.
Data on the primary outcome measure of sputum wet
weight were entered into the Cochrane Collaboration’s
Review Manager Software (RevMan 5.0) to enable calcula-
tion of pooled estimates using a random effects model.Data
from cross-over trials were incorporated using the generic
inverse variance method, involving expression of data in
terms of the paired mean differences between interven-
tions and their standard error.22 These values were calcu-
lated either from individual paired participant data, or by
calculation of mean differences between interventions and
their standard error from means, standard deviations, re-
ported p values and confidence intervals. For studies that
did not report paired results, but means and standard
deviations for each intervention, paired analyses were
approximated by assuming a degree of correlation between
the interventions, based on an average observed correla-
tion among the other studies. Sensitivity analyses with an
assumed correlation of zero were performed to assess the
impact of the assumed correlation on the outcome of the
meta-analysis.22
The overall effect of the intervention was reported using
standardised mean differences (SMDs).Ninety-five per cent
confidence intervals (95% CIs) were calculated for each
individual study and the pooled estimates. Heterogeneity
of studies was quantified using the I2 statistic with p < 0.05
considered statistically significant. Where significant
heterogeneity existed, studies and data were reviewed in
order to identify possible sources of variation.
Results
Flow of studies through the review
Five hundred and thirty nine titles were identified by the
electronic search and two publications identified through
contacting experts. Of these, 107 full text publications
were retrieved, of which 24 were included in the final
review. Reasons for exclusion of studies are presented in
Fig. 2.23
Characteristics of studies
Volume and risk of methodological bias of evidence
The volume of the evidence was assessed using the Lloyd-
Smith evidence hierarchy.17No studies fulfilled the criterion
for the highest level of evidence (1a, systematic reviews)and two randomised controlled trials were classified as
level 1b. Eighteen of the included studies were crossover in
design, with 11 of these classified as level 1b (clear ran-
domisation procedures) and seven as level 2a (unclear
randomisation procedures). The remaining four studies
were classified as level 2b. Risk of methodological bias
within studies ranged from two to nine points (Table 1)
(note: a maximum score of nine was possible only for
studies with a separate control group). The most common
methodological issues were inadequate reporting of sample
size justification (item 3, 19 studies) and absence of
a separate control group (item 4, 22 studies). Twelve of the
22 studies without a separate control group did not report
sufficient information regarding duration of the washout
period or stability of baseline measures (item 6).
Generalisability of evidence
Ninety-two per cent of the included studies included
participants with respiratory conditions with chronic
sputum production. Of these, the majority (n Z 16)
recruited participants with CF,3,7,24e37 four with non-CF
bronchiectasis6,38e40 and two investigated chronic bron-
chitis.8,41 The remaining studies included participants with
acute hypercapnic respiratory failure,42 and chronic
obstructive pulmonary disease (COPD).43 Therefore the
generalisability was classified as excellent with 92 per
cent (n Z 22) of the included studies carried out on
respiratory conditions with likely chronic sputum produc-
tion (Table 2).
Participants
Twelve of the 24 included studies quantified disease
severity using percentage of predicted FEV1. Using the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD)44 COPD severity classification system (mild  80,
moderate 50e80, severe 30e50, very severe < 30), the
severity of disease in 10 of the studies was classified as
moderate, and in two studies as severe. The remaining
studies did not report the FEV1(% predicted) at baseline. Nine
studies were undertaken with participants experiencing an
acute respiratory exacerbation.3,7,26,28,33e36,42
Thirteen studies were conducted exclusively on adults
(18 years).6e8,25,26,28,33,38e43 Nine studies were conducted
on a combination of adolescents (12e17 years) and
adults,3,24,27,29,30,32,34e36 and two studies included children
(<12 years) with adolescents and adults.31,37
Intervention
The majority of the included studies investigated the ACBT
(nZ 21), with the remaining three studies investigating the
FET. Fifteen studies involved single treat-
ments.6e8,25,26,29,30,32,34e38,40,41In four studies the duration
of each treatment arm was less than seven days.3,27,28,33
One study had a variable treatment time for each partici-
pant depending on the length of stay in the intensive care
unit but averaged approximately eight to nine days.42 In the
remaining four studies the duration of each treatment arm
ranged from three weeks to six months.24,31,39,43
Comparator/control
Ten of the included studies compared the intervention with
an oral device (n: 5 PEP, n: 3 flutter, n: 1 acapella, n: 1
Figure 2 PRISMA chart23 demonstrating the flow of studies through the review.
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thoracic oscillatory devices and AD. Only one study
compared ACBT to exercise prescribed for sputum clear-
ance (Table 3).
Outcome measures
A total of 35 outcome measures were identified in the
included studies. The most commonly reported outcomes
were sputum wet weight (n Z 17), FVC (n Z 12), FEV1
(n Z 12), and patient preference or acceptability of
treatment (n Z 10) (Table 4). As previously outlined,
outcomes relating to lung function are more likely to reflect
combined therapeutic strategies. Therefore, the outcomes
of participant preference and acceptability of treatment
and sputum wet weight were further explored for the
purposes of this review.Participant preference/acceptability
Ten studies involving 182 participants reported participant
preference or acceptability.6,7,25,29,31,35,37e40 The study by
Carr et al25 contained a five item questionnaire to assess
participant views on the self chest clapping component of
the intervention rather than the ACBT. The main findings
for participant preference and acceptability in relation to
FET/ACBT are summarised in Table 5.Sputum wet weight
Description of studies
Seventeen studies reported the primary outcome of sputum
wet weight. Two studies that investigated sputum wet
Table 1 Methodological quality of studies based on the LOWa critical appraisal tool for experimental studies.
Study 1 2 3 4 5 6 7 8 9a 9b Total (0e9)
Pryor & Webber 19793 Y Y N N N N N N Y Y 4
Inal-Ince et al 200442 Y Y Y Y Y N Y Y Y Y 9
Savci et al 200043 Y Y N Y Y N Y N Y Y 7
Blomquist et al 198624 Y Y N N N N Y Y Y Y 6
Carr et al 199525 Y Y N N N Y Y Y N Y 6
Pryor et al 199015 Y N N N N N Y N N N 2
Webber et al 198627 Y Y N N N N Y Y N Y 5
Murphy et al 198328 Y N N N N N N N Y N 2
Eaton et al 20076 Y Y Y N N Y Y Y Y Y 8
Falk et al 198429 Y Y N N N Y N Y N Y 5
Lannefors & Wollmer 199230 Y N N N N N N Y N Y 3
Patterson et al 200538 Y Y Y N N Y Y Y Y Y 8
Phillips et al 20047 Y Y N N N Y Y Y N Y 6
Steen et al 199131 Y Y N N N N N Y Y Y 5
Thompson et al 200239 Y Y Y N N Y N N N Y 5
van Hengstum et al 198832 Y N N N N N Y Y Y Y 5
Chatham et al 200433 Y Y N N N Y Y N N Y 5
Hofmeyr et al 198634 Y Y N N N Y N N N Y 4
Milne & Eales 200435 Y Y N N N Y N Y Y Y 6
Steven et al 199236 Y Y N N N N N Y N Y 4
Patterson et al 200440 Y Y Y N N Y Y Y Y Y 8
van Hengstum et al 19908 Y N N N N Y Y Y Y Y 6
van Hengstum et al 199141 Y N N N N N Y N Y Y 4
Miller et al 199537 Y Y N N N Y Y N Y Y 6
a LOW tool summary of criteria: 1. Did the study address a clearly focused issue? 2. Were the participants recruited in an acceptable
way? 3. Was there a sufficient number of participants? 4. Was there a separate control group? 5. Was there equal chance of participants
being allocated into either group? 6. Were the baseline measures stable? 7. Were the outcomes measured accurately to minimize bias? 8.
Have the confounding factors been accounted for? 9a. Were the results presented so the effect size was shown or could be calculated?
9b. Do you subjectively believe the results?.
ACBT: Systematic review and meta-analysis 161weight pre- and post ACBT did not report standard devia-
tions and were therefore unable to be included in the meta-
analysis.25,26 One study reported median values only and
was subsequently excluded.29 One further study reported
a significant beneficial effect of FET when compared to two
alternative interventions (Equi-med percussor and PD
p < 0.05, manual percussion and PD p < 0.05).28 However,
this study was completed on only two participants, and it
was unclear how the authors dealt with such a small sample
in the statistical analyses (LOW score 2/9). This study was
therefore excluded from the meta-analysis. A total of 13
studies involving 232 participants were included in the final
meta-analysis.
Nine studies reported sputum wet weight during and up
to 1 h post FET/ACBT.3,6,7,31,33,34,36,38,40 Three studies re-
ported 24 h post-treatment sputum wet weight8,32,35 and
one study reported four week accumulated sputum wet
weight.39
Available data and subsequent analyses
Two studies provided sufficient data (SDs for intervention
and comparator groups and for the mean difference
between groups) to enable calculation of correlation
coefficients between the intervention and comparator
groups (Eaton et al6 calculated correlation coefficient 0.80,
Milne et al35 0.90). Five studies reported sufficient data
(SDs for the intervention and comparator groups) to allow
for calculation of the SMD, but an imputed correlationcoefficient midway between the available coefficients
(0.85) was used to enable calculation of the SE(SMD) for
these studies.8,31e33,40 The remaining six studies contained
insufficient data (no reported SDs), and the imputed
correlation was used to subsequently calculate both the
SMD and the SE(SMD) to allow for inclusion of these studies in
the meta-analysis.3,7,34,36,38,39FET/ACBT versus all comparators
During and up to 1 h post-treatment
Nine studies involving 192 participants were included in
the final meta-analysis for sputum wet weight during and
up to 1 h post-treatment. One study7 provided two data
sets (morning and evening treatments), therefore 10 data
sets were included in the analysis. The FET/ACBT resulted
in no significant difference in sputum yield during and up
to 1 h post-treatment SMD 0.14 (95%CI -0.20e0.48)
with the studies demonstrating significant heterogeneity
(p < 0.00001).
Up to 24 h post-treatment
Three studies involving 23 participants reported 24 h
sputum wet weight. There was no significant difference
between FET/ACBT and the comparators in 24 h sputum
wet weight, SMD 0.18 (95%CI -0.08e0.44), and the studies
were shown to be homogeneous (p Z 0.11).
Table 2 Summary of all included studies.
Study Study design n Participant type and
age (years)
Description of intervention
and comparators
Outcomes measured
Pryor & Webber 19793 Randomised
crossover
trial (2 way)
16 CF
Age 20.5 (14e28)
1. CPT (PD, self percussion,
coughing, percussion
and shaking) þ thoracic
expansion exercises
2. ACBT (þPD, self percussion)
treatment time, sputum
wet weight
Inal-Ince et al 200442 Randomised
controlled trial
34
(2 groups
of n Z 17)
Intensive care
in-patients
with acute hypercapnic
respiratory failure
Age group 1: 65  8
Age group 2: 65  13
Group 1: ACBT (þvibrations
and shaking if copious
secretions) þ non-invasive
ventilation
Group 2: Control
(non-invasive
ventilation only)
length of time requiring non-
invasive ventilation, acute
physiology score, arterial blood
gas values, ICU length of stay
Savci et al 200043 Randomised
controlled trial
30
(n Z 15
each group)
COPD
Group 1: Age 58.3  8,
FEV1(%predicted): 39  14
Group 2: Age 61.3  7.9,
FEV1(%predicted): 41  18
Group 1: AD
Group 2: ACBT (þPD,
percussion and shaking)
lung function (FVC, FEV1,
PEFR, FEF25e75, FEF75e85),
oxygen saturation, arterial
blood gas information,
6 min walk test, dyspnoea
(modified Borg scale)
Blomquist et al 198624 Same subjects,
two step design
14 CF
Age: 17.8 (13e23)
FEV1(%predicted): 63.4
(44.2e112.9)
Phase A (6 months):
CPT (PD, percussion,
chest compressions)
þ increasing physical activity.
Phase B (6 months): ACBT
(relaxed controlled breathing,
3-4 deep breaths þ percussion,
relaxed controlled breathing,
1e2 huffs with self
percussion þ PD).
lung function (FVC, FEV1),
regional lung function,
arterial blood gas data
Carr et al 199525 Same subjects,
pre/post design
12 CF
Age 25.8 (18e50)
FEV1(%predicted):
31.8 (16e60)
ACBT þ self percussion until nil
sputum clearance, in patient’s
choice of PD position
lung function (FEV1, FVC),
SaO2, 6 MWT, sputum weight,
patient views
Pryor et al 199026 Same subjects,
pre/post design
20 CF
Age: 26.2 (19e34)
FEV1: 1.08 (0.60e2.40)
ACBT þ PD sputum weight, SaO2
Webber et al 198627 Same subjects
(pre/post design)
12 CF
Age: 19.5  4.1
FEV1(%predicted):
61.5  20.7
FET (þPD, percussion, shaking) lung function (FEV1, FVC,
TLC, RV, FRC, ERV,
alveolar volume, PEFR,
MEF50e75, PIFR,
index of gas trapping)
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Murphy et al 198328 Randomised
crossover
trial (3 way)
2 CF
Age: 19.5  3.5
1. PD and assisted percussion
(equi-med percussor)
2. PD and percussion by
a physiotherapist
3. ACBT (þPD)
sputum wet weight, lung
function (FEV1, FVC, PEFR)
Eaton et al 20076 Randomised
crossover
trial (3 way)
36 Non-CF bronchiectasis
Age: 62  10
FEV1(%predicted):
57.8  19.8
1: Flutter
2: ACBT
3: ACBT (DPD)
sputum wet weight, sputum
wet volume, patient
preference and acceptability,
lung function (FVC, FEV1),
oxygen saturation, dyspnoea
(Borg score)
Falk et al 198429 Randomised
crossover
trial (4 way)
14 CF
Age: 18 (14e30)
FEV1(% predicted):
54 (15e55)
1: PD, percussion
and vibrations
2: PEP (þPD)
3: PEP (sitting position)
4: FET (pursed lip
and diaphragm
breathing in sitting with
forced expirations with
open glottis)
sputum wet weight,
number of coughs,
peripheral oxygen delivery
(percutaneous
oxygen), lung function (FVC,
FEV1, PEFR), patient
acceptability, review of
radiographs
Lannefors & Wollmer 199230 Randomised
crossover
trial (3 way)
9 CF
Age: 24.8  7.7
FEV1(%predicted): 51  20.2
1: ACBT (þPD)
2: PEP (sitting) þ FET (PD)
3: physical exercise bike
ergometer þ FET (PD)
mucus clearance
(gamma camera)
Patterson et al 200538 Randomised
crossover
trial (2 way)
20 stable, productive bronchiectasis
Age: 58  11
FEV1(%predicted): 64  22
1: ACBT (þPD)
2: acapella
sputum wet weight, lung
function (FEV1, FVC, PEFR),
oxygen saturation,
breathlessness
(15 point score), no. of
coughs, patient preference,
treatment times
Phillips et al 20047 Randomised
crossover
design (2 way)
10 CF
Age: 59  9
FEV1(%predicted): 56.1  23.3
1. supervised use of the
Hayek oscillator
2. supervised ACBT (þPD)
sputum wet weight, lung
function (FVC, FEV1), heart
rate, oxygen saturation,
blood pressure, patient
preference
Steen et al 199131 Randomised
crossover
trial (4 way)
28 CF
Age: 14 (8e21)
FEV1(%predicted): 68 (15e114)
1: FET (þPD, percussion)
2: PEP (þPD, percussion, FET)
3: PEP (sitting)
4: PEP and FET (sitting).
sputum wet weight, lung
function (PEFR, FEV1, FVC),
patient preference
(continued on next page)
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Table 2 (continued)
Study Study design n
Participant type and
age (years)
Description of intervention
and comparators Outcomes measured
Thompson et al 200239 Randomised
crossover
trial (2 way)
17 non-CF bronchiectasis
Flutter first group:
Age 59  8,
FEV1(%predicted): 67  38.
ACBT first group: Age 68  16,
FEV1(%predicted): 70  42
1. Flutter
2. ACBT (þPD)
sputum wet weight,
treatment time, lung function
(PEFR, FEV1, FVC), dyspnoea
(Borg scale), chronic
respiratory disease
questionnaire,
patient preference
van Hengstum et al 198832 Randomised
crossover
trial (2 way)
8 CF (n Z 6)
Agammaglobulinaemia (n Z 2)
Age: 23 (15e27)
FEV1(%predicted): 65  29
1: CPT (PD, percussion,
directed coughing)
þ deep breathing
2: ACBT (þPD, chest
compressions)
regional clearance,
tracheobronchial clearance
Chatham et al 200433 Randomised
crossover
trial (2 way)
20 CF
Adults
1: ACBT(þPD and percussion)
2: RIM at 80% of maximal
sustained inspiratory pressure
sputum wet weight
Hofmeyr et al 198634 Randomised
crossover
trial (3 way)
18 CF
Age: 22.5 (13e37)
FEV1: 1.3 (0.45e3.25)
1: ACBT (þPD)
2: PEP (þPD, breathing
control, FET)
3: PEP (sitting, breathing
control, FET)
sputum wet weight,
lung function (FEV1, FVC),
oxygen saturation
Milne & Eales 200435 Randomised
crossover
trial (2 way)
7 CF
Age: 28 (16e42)
FEV1: 1.23 (no SD reported)
1: Flutter (10e15
exhalations) þ FET
2: ACBT
lung function (FEV1, FVC,
PEFR, FEF25e75, FIF50), sputum
wet weight, patient preference
Steven et al 199236 Randomised
crossover
trial (3 way)
24 CF
Age: 25 (17e33)
FEV1: 1.11 (0.44e2.72)
1. sit and cough (breathing
control in-between coughs)
2. ACBT (DPD)
3. ACBT (sitting)
sputum wet weight, lung
function (FEV1, FVC, FEF50,
FEF75), oxygen saturation
Patterson et al 200440 Randomised
crossover
trial (2 way)
20 non-CF bronchiectasis
Age: 54.4  14.4
1: ACBT (þPD, vibrations)
2: RIM at 80% of maximal
sustained inspiratory pressure
(test of incremental
respiratory endurance)
sputum wet weight, lung
function (FEV1, FVC, PEFR),
oxygen saturation, patient
preference
van Hengstum et al 19908 Randomised
crossover
trial (3 way)
8 Chronic bronchitis
Age: 60 (44e76)
FEV1(%predicted): 68  27
1: ACBT (þPD)
2: oral high frequency
oscillation
3: control (breathing
humidified air and huffing)
sputum wet weight, sputum
dry weight, tracheobronchial
clearance, lung function
(FEV1, FVC, MEF50)
van Hengstum et al 199141 Randomised
crossover
trial (3 way)
7 Chronic bronchitis
Age: 62 (48e73)
FEV1(%predicted): 56þ-21
1: PEP (þFET)
2ACBT (þPD)
3: control (only
spontaneous cough)
regional clearance
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ACBT: Systematic review and meta-analysis 165FET/ACBT versus individual comparators
The results of FET/ACBT compared to the individual
comparators are summarised in Table 6.
FET/ACBT versus RIM
During and up to 1 h post-treatment
Two studies involving 40 participants investigated sputum
wet weight up to 30 min post-treatment with ACBT and
RIM.33,40 There was no significant difference, SMD -1.08
(95%CI -3.85 to 1.70), with the studies demonstrating
significant heterogeneity (p < 0.00001). Considering these
studies separately, RIM resulted in a significant increase in
sputum wet weight compared to ACBT in patients with an
exacerbation of CF,33 SMD -2.5 (95%CI -2.99 to 2.01),
whereas ACBT resulted in a significant increase in sputum
wet weight compared to RIM in participants with chronic
bronchitis,31 SMD 0.33 (95%CI 0.08e0.58).
FET/ACBT versus CPT
During and up to 1 h post-treatment
One study involving 16 exacerbated CF participants
compared sputum wet weight up to 30 min post-treatment
between the interventions of ACBT and CPT.3 ACBT resulted
in a significant increase in sputum wet weight when
compared with CPT, SMD 0.32 (95%CI 0.05e0.59).
Up to 24 h post-treatment
One study involving eight CF participants compared 24 h
sputum wet weight between the interventions of ACBT and
CPT.32 There was no significant difference in 24 h sputum
yield between ACBT or CPT, SMD 0.07 (95%CI -0.30e0.44).
FET/ACBT versus PEP
During and up to 1 h post-treatment
Two studies involving 46 CF participants investigated
sputum wet weight during treatment with FET/ACBT as
opposed to PEP.31,34 There was no significant difference
between the two interventions for sputum wet weight, SMD
0.26 (95%CI -0.11e0.63), and the studies demonstrated
significant heterogeneity (p Z 0.04). Considering these
studies separately, ACBT resulted in a significant increase in
sputum wet weight in exacerbated CF participants,34 SMD
0.47 (95%CI 0.18e0.79), and there was no significant
difference between the interventions in stable CF partici-
pants,31 SMD 0.09 (0.11e0.29).
FET/ACBT versus oral oscillatory devices
During and up to 1 h post-treatment
Two studies involving 56 participants with bronchiectasis
investigated sputum wet weight up to 30 min post-
treatment with ACBT and the oral oscillatory devices of
flutter6 and acapella.38 There was no significant difference
between the two interventions for sputum wet weight, SMD
Table 3 Comparators for each of the included studies.
Study Intervention CPT RIM Oral
devices
Thoracic
devices
Exercise AD Control
Pryor & Webber 19793 ACBT
Inal-Ince et al 200442 ACBT NIV
Savci et al 200043 ACBT
Blomquist et al 198624 ACBT
Carr et al 199525 ACBT pre/post
Pryor et al 199026 ACBT pre/post
Webber et al 198627 FET pre/post
Murphy et al 198328 ACBT Equi-med
Eaton et al 20076 ACBT Flutter
Falk et al 198429 FET PEP
Lannefors & Wollmer 199230 ACBT PEP
Patterson et al 200538 ACBT Acapella
Phillips et al 20047 ACBT Hayek
Steen et al 199131 FET PEP
Thompson et al 200239 ACBT Flutter
van Hengstum et al 198832 ACBT
Chatham et al 200433 ACBT
Hofmeyr et al 198634 ACBT PEP
Milne & Eales 200435 ACBT Flutter
Steven et al 199236 ACBT sit & cough
Patterson et al 200440 ACBT
van Hengstum et al 19908 ACBT OHFO humid air, huff
van Hengstum et al 199141 ACBT PEP cough
Miller et al 199537 ACBT
Shaded cells denote the included comparator for each study.
ACBT Active cycle breathing technique, AD Autogenic drainage, CPT Conventional physiotherapy, NIV Non-invasive ventilation, OHFO
Oral high flow oscillation, PEP Positive expiratory pressure, RIM Resisted inspiratory manoeuvres.
166 L.K. Lewis et al.0.33 (95%CI -0.04e0.71), and the studies demonstrated
significant heterogeneity (p Z 0.02).
Up to 24 h post-treatment
Two studies involving 15 participants investigated 24 h
sputum wet weight post-treatment with ACBT and the oral
oscillatory devices of flutter35 and OHFO.8 There was no
significant difference between ACBT and oral devices for
sputum wet weight, SMD 0.16 (95%CI -0.38e0.70), and the
studies demonstrated significant heterogeneity (pZ 0.04).
Considering the studies separately, there was no difference
in 24 h sputum weight between ACBT and flutter for exac-
erbated CF participants, SMD -0.10 (95%CI -0.41 to 0.21),
and a significant increase in 24 h sputum weight in the ACBT
compared to OHFO in participants with chronic bronchitis,8
SMD 0.45 (95%CI 0.04e0.86).
Four week accumulated sputum wet weight
One study involving 17 non-CF bronchiectasis participants
compared four week accumulated sputum wet weight
between ACBT and the flutter device.39 There was no
significant difference between the two interventions in four
week sputum yield, SMD 0.04 (95%CI -0.21e0.29).
FET/ACBT versus external oscillatory devices
During and up to 1 h post-treatment
One study involving 10 exacerbated CF participants
compared sputum wet weight up to 15 min post-treatmentbetween ACBT and the Hayek oscillator.7 This study
collected data from both morning and evening treatments,
and these data sets were treated separately in the meta-
analysis. The ACBT demonstrated a significant increase in
sputum yield when compared to the Hayek oscillator, SMD
0.75 (95%CI 0.48e1.02), with these studies shown to be
homogeneous (p Z 0.45).
FET/ACBT versus control
During and up to 1 h post-treatment
One study involving 24 exacerbated CF participants
compared during treatment sputum wet weight between
ACBT and a control.36 ACBT resulted in a significant increase
in sputum wet weight when compared with the control,
SMD 0.24 (95%CI 0.02e0.46).
Up to 24 h post-treatment
One study involving eight participants with chronic bron-
chitis compared 24 h sputum wet weight between ACBT and
a control.8 There was no significant difference, SMD 0.38
(95%CI -0.01e0.77).
Sensitivity analysis
In studies where raw or grouped paired data were not
available, paired analyses were approximated by assuming
a level of correlation between the intervention and
Table 4 Outcome measures found in multiple studies.
Study Study
design
Sputum
wet weight
FVC
FEV1
Patient
values
SaO2 PEFR Regional
clearance
Radio
aerosol
retention
Sputum
clearance
rate
pH FEF25e75,
FEF75e85
Borg Airways
conductance
Pryor & Webber 19793 Crossover
Inal-Ince et al 200442 RCT
Savci et al 200043 RCT
Blomquist et al 198624 Two step
Carr et al 199525 Pre/post
Pryor et al 199026 Pre/post
Webber et al 198627 Pre/post
Murphy et al 198328 Crossover
Eaton et al 20076 Crossover
Falk et al 198429 Crossover
Lannefors & Wollmer 199230 Crossover
Patterson et al 200538 Crossover
Phillips et al 20047 Crossover
Steen et al 199131 Crossover
Thompson et al 200239 Crossover
van Hengstum et al 198832 Crossover
Chatham et al 200433 Crossover
Hofmeyr et al 198634 Crossover
Milne & Eales 200435 Crossover
Steven et al 199236 Crossover
Patterson et al 200440 Crossover
van Hengstum et al 19908 Crossover
van Hengstum et al 199141 Crossover
Miller et al 199537 Crossover
Shaded cells denote the included outcome measures for each study.
FEF Forced expiratory flow, FEV1 Forced expiratory volume in 1 s, FVC forced vital capacity, PEFR Peak expiratory flow rate, RCT Randomised controlled trial, SaO2 Arterial oxygen
saturation.
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Table 5 Summary of participant preference findings from the included studies.
Study n Intervention/comparator Participant preference/
acceptability
Eaton et al 20076 36 ACBT þ PD, ACBT, Flutter 33% preferred ACBT þ PD, 22%
ACBT, 44% flutter
Falk et al 198429 14 FET, CPT, PEP þ PD, PEP (sitting) 79% preferred PEP (sitting)
Patterson et al 200538 20 ACBT, Acapella A greater proportion of
participants preferred acapella
to ACBT but this was not
significant (MD 0.4, 95%CI
0.04e0.71)
Phillips et al 20047 10 ACBT, Hayek oscillator All participants reported that
the ACBT was comfortable, 60%
reported the Hayek oscillator
was uncomfortable, and 80%
reported that it was difficult to
clear secretions with the Hayek
oscillator compared to ACBT
Steen et al 199131 28 FET, PEP þ PD, PEP (sitting),
PEP þ FET
96% of participants chose
PEP þ FET as their long term
treatment program at the
completion of the study
Thompson et al 200239 17 ACBT, Flutter 65% preferred flutter versus
ACBT for long term use
Milne & Eales 200435 7 ACBT, Flutter 43% preferred ACBT, 29%
flutter, 29% no preference
Patterson et al 200440 20 ACBT, RIM 55% reported that ACBT was
more effective, 20% RIM, 25%
no preference. 50% preferred
ACBT and 50% preferred RIM for
home treatment
Miller et al 199537 18 ACBT, AD 44% preferred ACBT, 50% AD, 6%
no preference
AD Autogenic drainage, CPT Conventional physiotherapy, PEP Positive expiratory pressure, PD Postural drainage, RIM Resisted inspiratory
manoeuvres.
168 L.K. Lewis et al.comparator outcomes.45 In this review, a correlation of
0.85 was assumed which was the mean of the two available
correlation coefficients.6,35 Sensitivity analyses were per-
formed to assess the impact of the assumed correlation on
the meta-analysis by repeating the analysis assuming zeroTable 6 Sputum wet weight effect estimates per comparator.
Comparator Sputum weight
collection time
Studies (n) P
RIM During e 30 min 2 4
CPT During e 30 min 1 1
24 h 1
PEP During e 30 min 2 4
Oral devices During e 30 min 2 5
24 h 2 1
4 week 1 1
External devices During e 30 min 1a 1
Control During e 30 min 1 2
24 h 1
CPT Conventional physiotherapy, N/A not applicable, PEP Positive
Standardised mean difference Shaded cells denote significant overall
a Phillips et al., 2004 contained morning and evening data sets whicorrelation.21,22 As to be expected by assuming such
a conservative correlation, there was a general widening of
the confidence intervals. In studies where the intervention
and comparator group standard deviations were unavail-
able, the assumed correlation was used to calculate thearticipants (n) Overall effect estimate
SMD (95%CI)
Heterogeneity
0 1.08 (3.85 to 1.70) p < 0.00001
6 0.32 (0.05 to 0.59) N/A
8 0.07 (0.30 to 0.44) N/A
6 0.26 (0.11 to 0.63) p Z 0.04
6 0.33 (0.04 to 0.71) p Z 0.02
5 0.16 (0.38 to 0.70) p Z 0.04
7 0.04 (0.21, 0.29) N/A
0 0.75 (0.48 to 1.02) p Z 0.40
4 0.24 (0.02 to 0.46) N/A
8 0.38 (0.01 to 0.77) N/A
expiratory pressure, RIM Resisted inspiratory manoeuvres, SMD
effect (p < 0.05).
ch were treated separately in the meta-analysis.
ACBT: Systematic review and meta-analysis 169SMD as well as the SE(SMD), therefore there was an obvious
effect on the overall effect estimate (Table 7). Two studies
showed a moderate increase in the effect estimate with the
conservative correlation,7,34 with the remaining studies
demonstrating differences of small magnitude. These
differences did not impact greatly on the significance of the
findings, with only two studies losing significance of the
overall effect of ACBTwith the conservative estimation due
to a small shift in the confidence intervals.8,40Discussion
The techniques of FET/ACBT were shown to have a more
beneficial short-term effect on sputum wet weight when
compared to CPT, external oscillatory devices and
a control. There was no clear evidence of a beneficial short-
term effect on sputum wet weight when compared to RIM
and PEP, or in the 24 h post-treatment when compared to
CPT, oral devices or a control. There was limited evidence
that the participants in the majority of studies preferred
other treatment techniques to FET/ACBT.
The FET/ACBT were investigated against a wide range of
comparator interventions, which made comparison of the
various studies difficult. There was only one study which
investigated the efficacy of FET/ACBT compared to exercise
prescribed specifically for sputum clearance. There were
a small number of studies which compared the intervention
to a control intervention. In order to investigate the true
efficacy of FET/ACBT, more studies are needed that inves-
tigate the technique against a control rather than a compar-
ator intervention with similar treatment aims. Whether it is
ethical to include a control (no airway clearance interven-
tion) is likely to be controversial especially in protocolswhich
seek to recruit people with chronic respiratory conditionsTable 7 Sensitivity analyses for the primary outcome of sputum
Study Meta-analysi
(correlation
0.85) SMD (9
Pryor & Webber 19793 0.32 [0.05 t
Eaton et al 20076 0.52 [0.30 t
Patterson et al 200538 0.14 [0.10
Phillips et al 2004a,7 0.86 [0.47 t
Phillips et al 2004b,7 0.65 [0.28 t
Steen et al 199131 0.09 [0.11
Thompson et al 200239 0.04 [0.21
van Hengstum et al 198832 0.07 [0.30
Chatham et al 200433 2.50 [2.99
Hofmeyr et al 198634 0.47 [0.18 t
Milne & Eales 200435 0.10 [0.41
Steven et al 199236 0.24 [0.02 t
Patterson et al 200440 0.33 [0.08 t
van Hengstum et al 1990a,8 0.45 [0.04 t
van Hengstum et al 1990b,8 0.38 [0.01
SMD Standardised mean difference.
Effect estimates shown in bold denote significant overall effect (p <
Shaded cells represent studies where the SMD and the SE(SMD) were c
a First data set.
b Second data set.during an acute exacerbation or during longitudinal cohort
studies. If the experimental control is defined as ‘no
prescribed intervention’, this could be inferred to mean that
the participants can only cough, huff, exercise or perform
formal airway clearance techniques as required. As people
with chronic secretion-producing respiratory diseases will by
necessity cough or huff, a control intervention might essen-
tially mean airway clearance techniques are still performed
but in a less prescribed way. While there is a lack of
compelling long term studies of airway clearance techniques
in slowing disease progression or reducing reliance of health
care for people with chronic secretion producing conditions,
it is currently unlikely that ethical approval would be granted
to conduct studies that prospectively plan a control inter-
vention in conditions such as cystic fibrosis. It is possible that
such studies could be conducted in participants with non-CF
bronchiectasis, as there is no consensus about the prescrip-
tion or efficacy of airway clearance techniques in this
population.46
Two protocols for systematic reviews of airway clear-
ance techniques have recently been published. The primary
aim of these protocols is to determine the effects of airway
clearance techniques on the rate of exacerbations, hospi-
talisations and quality of life in people with acute and
stable COPD47 and bronchiectasis46 respectively. While
these reviews, once completed, are likely to include the
airway clearance techniques of FET/ACBT, the comparators
planned will not consider alternative airway clearance
techniques, other than cough alone. Hence the overlap
between the current review and the prospectively planned
reviews is likely to be minimal.
Given the range of proposed mechanisms for FET/ACBT,
it was unclear whether the corpus of studies would be
skewed toward assessment of outcomes at the ultimate
endpoint (i.e. quality of life or exercise tolerance) or thewet weight.
s
coefficient
5%CI)
Sensitivity analysis
(correlation coefficient
0.00) SMD (95%CI)
o 0.59] 0.83 [0.03 to 1.63]
o 0.74] 0.52 [0.30 to 0.74]
to 0.38] 0.37 [-0.28 to 1.02]
o 1.25] 2.20 [0.57 to 3.83]
o 1.02] 1.67 [0.32 to 3.02]
to 0.29] 0.09 [0.44 to 0.62]
to 0.29] 0.10 [-0.57 to 0.77]
to 0.44] 0.07 [-0.91 to 1.05]
to 2.01] 2.50 [3.07 to 1.93]
o 0.76] 1.20 [0.34 to 2.06]
to 0.21] 0.10 [0.41 to 0.21]
o 0.46] 0.78 [0.13 to 1.43]
o 0.58] 0.33 [0.30 to 0.96]
o 0.86] 0.45 [0.57 to 1.47]
to 0.77] 0.38 [0.64 to 1.40]
0.05).
alculated using an estimated correlation coefficient.
170 L.K. Lewis et al.proximal end of the causal chain (sputum clearance,
ventilation), on the assumption that changes at this level
would be likely to result in long term beneficial outcomes.
As a rule, assessment of the effectiveness of interventions
should take place at the distal end of the putative chain
thus avoiding assumptions about links between interme-
diate steps. Unfortunately, measuring outcomes at the
distal end of the causal chain often requires long-term
follow-up studies, and outcomes are not always as
measurable as those at the proximal end. In this review, the
impact of FET/ACBT was assessed using a variety of
outcome measures. When these are allocated along the
causal chain, the paucity of outcomes assessing the ulti-
mate endpoint becomes apparent. The most common
outcome variable was sputum wet weight which reflected
the short term outcome of the interventions. The potential
limitations of sputum wet weight as an outcome measure
has been previously documented with concerns over day to
day variability, and measurement inaccuracies associated
with underestimation (swallowing of sputum), or over-
estimation (saliva).6 Despite the potential for measurement
inaccuracy, sputum wet weight has been shown to be as
reliable as dry sputum,1,48 and a common and clinically
useful outcome of airway clearance techniques.11
The lung function variables of FVC and FEV1 were
commonly evaluated but it could be argued that these
outcomes are of limited value in assessing the efficacy of
airway clearance techniques given the short-term duration
of the majority of studies and the documented day to day
variance in these measures. Such great variability in these
outcomes could mean that only massive changes would
reach statistical significance. There was a distinct lack of
studies reporting the impact of FET/ACBT on goals such as
quality of life, survival, or exercise tolerance. Single studies
only were available which assessed exercise tolerance or
health-related quality of life. Therefore, the majority of
studies investigating the intervention were concerned with
short term rather than longer term outcomes.
This systematic review aimed to consider the body of
evidence underpinning FET/ACBT rather than in specific
populations or clinical situations. Accordingly, this review
restricted inclusion of studies to research design and inter-
vention. The likelihood of missing studies was minimised
through a comprehensive search strategy and consultation
with experts in the field. The intent and findings of this
review do not negate the existence of other forms of
research evidence. Additionally, studies were excluded if
they investigated FET/ACBT in conjunction with other
techniques such as PEP or CPT. Therefore the implications of
this review may only be applied to situations where the
techniques of FET/ACBT are applied as the sole intervention
and should not be extrapolated to regimens which incorpo-
rate these techniques as part of a combined therapy.
This review used a modified version of the NHMRC15 body
of evidence matrix to assist in classifying the overall volume
and consistency of the evidence. The overall volume of
evidence for FET/ACBT was classified as good. The majority
of the studies included in this review (54%) were classified
as Level 1b which is the second highest level that experi-
mental study designs can be placed in the Lloyd-Smith17
hierarchy. The consistency of the evidence was also clas-
sified as good as indicated by consistency of the findingsacross most studies. Some heterogeneity was present which
most likely results from the diversity of study designs,
comparator interventions, and outcome variables included
in the studies.
Implications for clinical practice
This review clearly indicates that there is high level, variable
risk of bias evidence which indicates that FET/ACBT is at
least comparablewith other airway clearance techniques for
short term improvements in secretion removal. Based on
these findings, clinicians planning to use FET/ACBT as an
airway clearance technique for short-term secretion
removal can be confident of the efficacy of the technique in
comparison with other airway clearance techniques.
However, it is important that clinicians monitor patient
acceptability and therefore adherence to treatment, due to
the limited evidence that patients prefer other airway
clearance techniques over FET/ACBT. There is currently
insufficient evidence to make clinical recommendations
concerning the use of FET/ACBT for longer-term outcomes
such as quality of life or improved exercise tolerance.
Implications for research
This review has highlighted the piecemeal nature of
experimental research concerning the FET/ACBT. There
were only a small number of studies which investigated
participant preference, with the majority of participants
preferring to use alternative techniques for secretion
clearance over the FET/ACBT. Given the necessary adher-
ence to treatment in conditions such as CF, further research
is warranted in this area. Of the 24 included studies, only
four investigated the FET/ACBT in isolation, with the
remainder investigating the technique in conjunction with
PD, percussion or shaking. The inclusion of other techniques
with FET/ACBT, while possibly indicative of clinical prac-
tice, makes comparison of studies, and the effects of the
FET/ACBT difficult to isolate. Other airway clearance
techniques such as PEP and flutter were shown in this
review to be preferred by patients for airway clearance. It
would be useful for further research to investigate FET/
ACBT þ/ PD which could be completed independently,
with other airway clearance techniques.
While the current review demonstrates a reasonable body
of evidence around the intermediate outcome of sputumwet
weight, this is insufficient to draw evidence based guidelines
for the FET/ACBT. There is a need for studies investigating
FET/ACBT, possibly compared to a parallel control or
placebo intervention, and for studies with longer-term
treatment arms. There is an obvious deficiency in the lack
of information concerning longer-term outcomes and FET/
ACBT. In light of these deficiencies, the effectiveness of
FET/ACBT in people with mild, moderate and severe
pulmonary impairment needs to be further explored.
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Databases: AMED, MEDLINE, CINAHL, Scopus, Web of
Science and the Cochrane Library.
The search strategy included all commonly used terms
for the FET/ACBT interventions. A reference to the type of
therapy was included with the huffing search terms in order
to specifically target the airways clearance technique of
huffing rather than the forced expiratory manoeuvre
required in pulmonary function testing.Database Search terms and strategy
AMED and MEDLINE
n:107
1 ACBT
2 “active cycle breathing technique$”
3 “active cycle of breathing”
4 “forced expirat$ technique$”
5 {(huff or huffing) AND
(chest or lung or respirat$
or expirat$ or breath$)}
Limit to human studies in
the English language
CINAHL
n:41
1 ACBT
2 active cycle breathing technique*
3 active cycle of breathing
4 forced expirat* technique*
5 {(huff or huffing) AND
(chest or lung or respirat*
or expirat* or breath*)}
Limit to the English language
Scopus
n:150
1 ACBT
2 active cycle breathing technique*
3 active cycle of breathing
4 forced expirat* technique*
5 {(huff or huffing) AND
(chest or lung or respirat*
or expirat* or breath*)}
Limit to the English language
Web of Science
n:128
1 ACBT
2 active cycle breathing technique*
3 active cycle of breathing
4 forced expirat* technique*
5 {(huff or huffing) AND
(chest or lung or respirat*
or expirat* or breath*)}
Limit to the English language
The Cochrane
Library n:113
1 ACBT
2 active cycle breathing technique*
3 active cycle of breathing
4 forced expirat* technique*
5 {(huff or huffing) AND
(chest or lung or respirat*
or expirat* or breath*)}
Limit to the English language
ACBT Active cycle breathing technique.
$* e truncation symbols for the relevant databases.References
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